Massive pulmonary embolism and ulcerative colitis

Hellenic Journal of Cardiology

Volumn 49, Issue 5, 2008, Pages 365-370

  Kafkas, Nikolaos V ^a,b   Deboneras, Christos C ^a   Babalis, Dimitrios K ^a  

^a KAT HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Inflammatory bowel disease; Pulmonary embolism

Indexed keywords

ALTEPLASE; COUMARIN; HEPARIN; MESALAZINE; PREDNISOLONE;

ADULT; ANAMNESIS; ARTICLE; BLOOD CLOT LYSIS; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENTERITIS; HUMAN; LUNG EMBOLISM; MALE; RISK ASSESSMENT; SHOCK; ULCERATIVE COLITIS; ULTRASOUND;

EID: 57349194217     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bargen J, Barker N. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med. 1936; 58: 17-31.
2. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. Q J Med. 1997; 90: 183-188.
3. Jain S, Bhatt P, Muralikrishna K, Malhotra P, Kumari S, Varma S. Extensive arterial and venous thrombosis in a patient with ulcerative colitis-A case report. General Medicine. 2005; 7: 10.
4. Elliott HL. Thrombophlebitis migrans: a further systemic complication of ulcerative colitis. Postgrad Med J. 1980; 56: 207-208.
5. Hatoum OA, Binion DG, Otterson MF, et al. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology. 2003; 125: 58-69.
6. Crespo I, Murphy J, Wong RK. Superior mesenteric venous thrombosis masquerading as Crohn's disease. Am J Gastroenterol. 1994; 89: 116-118.
7. Dhillon AP, Anthony A, Sim R, et al. Mucosal capillary thrombi in rectal biopsies. Histopathology. 1992; 21: 127-133.
8. Pogliani EM, Bozzan A, Radaelli F. Thrombolytic therapy for venous thrombosis in patients with gastrointestinal diseases. Pharmatherapeutica. 1982; 3: 268-273.
9. Van Vanwoert JH, Thomson RC, Cangemi JR, Metzger PP, Blackshear JL, Fleming CR. Streptokinase therapy for extensive venous thrombosis in a patient with severe ulcerative colitis. Mayo Clinic Proc. 1990; 65: 1144-1149.
10. Elikowski W, Malec M, Lawandowska M. Massive pulmonary embolism in a patient with ulcerative colitis and hyperhomocysteinaemia-a case report. Kardio Pol. 2006; 64: 405-409.
11. Talbot RW, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986; 61: 140-145.
12. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004; 53: 542-548.
13. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993; 34: 247-251.
14. Novotny DA, Rubin RJ, Slezak FA, et al. Arterial thromboembolic complications of inflammatory bowel disease: report of three cases. Dis Colon Rectum. 1992; 35: 193-196.
15. Irving P, Pasi J, Rampton D. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2005; 3: 617-628.
16. Bernstein C, Blanchard J, Houston D, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost. 2001; 85: 430-434.
17. Solem CA, Loftus EV, Tremaine WJ, et al. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004; 99: 97-101.
18. Magro F, Dinis-Ribeiro M, Araujo FM, et al. High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003; 15: 1157-1163.
19. Cattaneo M, Vecchi M, Zighetti M, et al. High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost. 1998; 80: 542-545.
20. Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin B(6) plasma levels, a risk factor for thrombosis in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol. 2003; 98: 112-117.
21. Haagsma CJ, Blom HJ, Van Riel PLCM, et al. Influence of sulphasalazine, methotrexate and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis. 1999; 58: 79-84.
22. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998; 338: 1042-1050.
23. Joseph L, Fink LM, Hauer-Jensen M. Cytokines in coagulation and thrombosis: a preclinical and clinical review. Blood Coagul Fibrinolysis. 2002; 13: 105-116.
24. Schafer AI. Thrombocytosis. N Engl J Med. 2004; 350: 1211-1219.
25. Danese S, De la Motte C, Sturm A, et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology. 2003; 124: 1249-1264.
26. Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation. 2001; 104: 2266-2268.
27. Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Card. 2001; 38: 1002-1006.
28. Joseph JE, Harrison P, Mackie JM, et al. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol. 2001; 115: 451-459.
29. Irving PM, Macey MG, Webb L, et al. Formation of platelet-leucocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 361-372.
30. Robert JH, Sachar DB, Aufses AH, Greenstein AJ. Management of severe hemorrhage in ulcerative colitis. Am J Surg. 1990; 159: 550-555.
31. Papa A, Danese A, Gasbarrini A, et al. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther. 2000; 14: 1403-1409.
32. Ang YS, Mahmud N, White B, et al. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther. 2000; 14: 1015-1022.
33. Panes J, Esteve M, Cabre E, et al. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology. 2000; 119: 903-908.
34. Bloom S, Kiilerich S, Lassen MR, et al. Low molecular weight heparin (tinzaparin) vs placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2004; 19: 871-878.
35. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53 (Suppl 5): V1-V16.
36. Task Force on Pulmonary Embolism of the European Society of Cardiology. Guidelines on diagnosis, management of acute pulmonary embolism. Eur Heart J. 2000; 21: 1301-1336.
37. N. Kucher, CM Luder, T. Dornhofer, S. Windecker, B. Meier, OM Hess. Novel management strategy for patients with suspected pulmonary embolism. Eur Heart J. 2003; 24: 366-376.
38. Kostadima E, Zakynthinos E. Pulmonary embolism: pathophysiology, diagnosis, treatment. Hellenic J Cardiol. 2007; 48: 94-107.
39. Teefy AM, Martin JE, Kovacs MJ. Warfarin resistance due to sulfasalazine. Ann Pharmacother. 2001; 35: 506.
40. Freeman HJ. Venous thromboembolism with inflammatory bowel disease. World J Gastroenterology. 2008; 14: 991-993.